Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major
cause of transplant-related mortality. Some of these infections are preventable by …

The objective of this study was to perform a systematic review of the literature on vaccine
responsiveness in patients who have received anti-CD20 therapy. PubMed and EMBASE …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

An international panel of experts prepared an evidenced-based guideline for vaccination of
immunocompromised adults and children. These guidelines are intended for use by primary …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …

Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across …

Guidelines for preventing infectious complications among hematopoietic cell transplant
recipients: a global perspective | Bone Marrow Transplantation Skip to main content Thank you …

Background Rituximab has altered the treatment approach to B-cell malignancies and other
diseases. Reports consider that rituximab had limited impact on serum immunoglobulins …

Purpose The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is
salvage chemotherapy followed by high-dose therapy and autologous stem-cell …

Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard
therapy for patients with CD20-expressing B-cell lymphoma, and is currently under …